Shuoming Luo

Shuoming Luo

Auto-generated profile, based on publicly available information

Shuoming Luo

National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2019 in Journal of Medical Internet Research
Verified
Journal Article
Open access
YZYiyu Zhang
Yiyu Zhang
CLChaoyuan Liu
Chaoyuan Liu
SLShuoming Luo
Shuoming Luo
YXYuting Xie
Yuting Xie
FLFang Liu
Fang Liu
ZZZhiguang Zhou
Zhiguang Zhou
Background: Diabetes poses heavy social and economic burdens worldwide. Diabetes management apps show great potential for diabetes self-management. However, the adoption of diabetes management apps by diabetes patients is poor. The factors influencing patients’ intention to use these apps are unclear. Understanding the patients’ behavioral intention is necessary to support the development and promotion of diabetes app use. Objective: This study aimed to identify the determinants of patients’ intention to use diabetes management apps based on an integrated theoretical model. Methods: The hypotheses of our research model were developed based on an extended Unified Theory of Acceptance and Use of Technology (UTAUT). From April 20 to May 20, 2019, adult patients with diabetes across China, who were familiar with diabetes management apps, were surveyed using the Web-based survey tool Sojump. Structural equation modeling was used to analyze the data. Results: A total of 746 participants who met the inclusion criteria completed the survey. The fitness indices suggested that the collected data fit well with the research model. The model explained 62.6% of the variance in performance expectancy and 57.1% of the variance in behavioral intention. Performance expectancy and social influence had the strongest total effects on behavioral intention (β=0.482; P=.001). Performance expectancy (β=0.482; P=.001), social influence (β=0.223; P=.003), facilitating conditions (β=0.17; P=.006), perceived disease threat (β=0.073; P=.005), and perceived privacy risk (β=–0.073; P=.012) had direct effects on behavioral intention. Additionally, social influence, effort expectancy, and facilitating conditions had indirect effects on behavioral intention that were mediated by performance expectancy. Social influence had the highest indirect effects among the three constructs (β=0.259; P=.001). Conclusions: Performance expectancy and social influence are the most important determinants of the intention to use diabetes management apps. Health care technology companies should improve the usefulness of apps and carry out research to provide clinical evidence for the apps’ effectiveness, which will benefit the promotion of these apps. Facilitating conditions and perceived privacy risk also have an impact on behavioral intention. Therefore, it is necessary to improve facilitating conditions and provide solid privacy protection. Our study supports the use of UTAUT in explaining patients’ intention to use diabetes management apps. Context-related determinants should also be taken into consideration.

8 February 2019 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
YZYiyu Zhang
Yiyu Zhang
XLXia Li
Xia Li
SLShuoming Luo
Shuoming Luo
CLChaoyuan Liu
Chaoyuan Liu
YXYuting Xie
Yuting Xie
ZZZhiguang Zhou
Zhiguang Zhou
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: The diabetes disease burden in China is heavy, and mobile apps have great potential for diabetes management. However, there is a lack of investigation of diabetes app use among Chinese diabetes patients and diabetologists. The perspectives and attitudes of diabetes patients and diabetologists regarding diabetes apps are also not clear. Objective: Our objectives were to investigate diabetes patients’ and diabetologists’ use, attitudes and perspectives, as well as patients’ needs, with respect to diabetes apps to provide information about the design of diabetes apps and how to best promote their use. Methods: Diabetes patients and diabetologists throughout China were surveyed on the WeChat (Tencent Corp) network using Sojump (Changsha ran Xing InfoTech Ltd) from January 23, 2018, to July 30, 2018. Differences among groups were compared using chi-square tests. Multivariate regression analysis was used to identify associations of demographic and basic disease information with app usage among adult patients. Results: Overall, 1276 individuals from 30 provincial administrative regions responded to the patient survey; among them, the overall app awareness rate was 29.94% (382/1276), and usage was 15.44% (197/1276). The usage was higher among type 1 diabetes (T1DM) patients than among type 2 diabetes (T2DM) patients (22.8%, 108/473 VS 10.8%, 79/733; P<0.001). Multivariate regression analysis showed that diabetes type, age, education, family income and location were associated with app use in adult patients. The need for and selection of diabetes apps were a little different between T1DM and T2DM patients. The reasons why patients discontinued the use of an app included limited time (29.9%, 59/197), complicated operations (25.4%, 50/197), ineffectiveness for glycemic control (24.4%, 48/197) and cost (19.3%, 38/197). Of the 610 responders to the diabetologist survey, 40.5% (247/610) recommended diabetes apps to patients, and 25.2% (153/608) used diabetes apps to manage patients. The greatest obstacles to diabetologists’ use of apps to manage diabetes patients include limited time (46.1% , 280/608), issues of legality (21.2%, 129/608), patients’ distrust (17.8%, 108/608) and issues with charging (10.9%, 66/608). Conclusions: The awareness and use of diabetes apps in Chinese diabetic patients and the proportion of diabetologists using diabetes apps to manage patients are low. Designing apps targeting different patient needs and conducting high-quality randomized controlled trials (RCT) will improve the effectiveness of apps, provide evidence for patients to choose suitable apps, and be conducive to the promotion of app use.

21 September 2018 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
YZYiyu Zhang
Yiyu Zhang
XLXia Li
Xia Li
SLShuoming Luo
Shuoming Luo
CLChaoyuan Liu
Chaoyuan Liu
FLFang Liu
Fang Liu
ZZZhiguang Zhou
Zhiguang Zhou
Background: With the popularity of mobile phones, mobile apps have great potential for the management of diabetes, but the effectiveness of current diabetes apps for type 1 diabetes mellitus (T1DM) is poor. No study has explored the reasons for this deficiency from the users’ perspective. Objective: The aims of this study were to explore the perspectives and needs of T1DM patients and diabetes experts concerning a diabetes app and to design a new T1DM management mobile app. Methods: A mixed-methods design combining quantitative surveys and qualitative interviews was used to explore users’ needs and perspectives. Experts were surveyed at 2 diabetes conferences using paper questionnaires. T1DM patients were surveyed using Sojump (Changsha ran Xing InfoTech Ltd) on a network. We conducted semistructured, in-depth interviews with adult T1DM patients or parents of child patients who had ever used diabetes apps. The interviews were audio-recorded, transcribed, and coded for theme identification. Results: The expert response rate was 63.5% (127/200). The respondents thought that the reasons for app invalidity were that patients did not continue using the app (76.4%, 97/127), little guidance was received from health care professionals (HCPs; 73.2%, 93/127), diabetes education knowledge was unsystematic (52.8%, 67/127), and the app functions were incomplete (44.1%, 56/127). A total of 245 T1DM patient questionnaires were collected, of which 21.2% (52/245) of the respondents had used diabetes apps. The reasons for their reluctance to use an app were limited time (39%, 20/52), complicated operations (25%, 13/52), uselessness (25%, 13/52), and cost (25%, 13/52). Both the experts and patients thought that the most important functions of the app were patient-doctor communication and the availability of a diabetes diary. Two themes that were useful for app design were identified from the interviews: (1) problems with patients’ diabetes self-management and (2) problems with current apps. In addition, needs and suggestions for a diabetes app were obtained. Patient-doctor communication, diabetes diary, diabetes education, and peer support were all considered important by the patients, which informed the development of a prototype multifunctional app. Conclusions: Patient-doctor communication is the most important function of a diabetes app. Apps should be integrated with HCPs rather than stand-alone. We advocate that doctors follow up with their patients using a diabetes app. Our user-centered method explored comprehensively and deeply why the effectiveness of current diabetes apps for T1DM was poor and what T1DM patients needed for a diabetes app and provided meaningful guidance for app design.

5 August 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
WYWenfeng Yin
Wenfeng Yin
SLShuoming Luo
Shuoming Luo
ZXZilin Xiao
Zilin Xiao
ZZZiwei Zhang
Ziwei Zhang
BLBingwen Liu
Bingwen Liu
ZZZhiguang Zhou
Zhiguang Zhou
Latent autoimmune diabetes in adults (LADA) is a heterogeneous disease sharing some phenotypic, genetic, and immunological features with both type 1 and 2 diabetes. Patients with LADA have a relatively slow autoimmune process and more residual islet β-cell function at onset, allowing a time window to protect residual islet β cells and delay or inhibit disease progression. It is crucial to discover various heterogeneous factors affecting islet β-cell function for precise LADA therapy. In this review, we first describe the natural history of LADA. Thereafter, we summarize β-cell function-related heterogeneous factors in LADA, including the age of onset, body mass index, genetic background, and immune, lifestyle, and environmental factors. In parallel, we evaluate the impact of current hypoglycemic agents and immune intervention therapies for islet β-cell protection. Finally, we discuss the opportunities and challenges of LADA treatment from the perspective of islet β-cell function protection.

7 January 2011 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
PJPing Jin
Ping Jin
GHGan Huang
Gan Huang
JLJian Lin
Jian Lin
SLShuoming Luo
Shuoming Luo
ZZZhiguang Zhou
Zhiguang Zhou

26 October 2022 in Frontiers in Genetics
Verified
Journal Article
Open access
WYWenfeng Yin
Wenfeng Yin
ZZZiwei Zhang
Ziwei Zhang
ZXZilin Xiao
Zilin Xiao
XLXia Li
Xia Li
SLShuoming Luo
Shuoming Luo
ZZZhiguang Zhou
Zhiguang Zhou
A novel class of non-coding RNA transcripts called circular RNAs (circRNAs) have been the subject of significant recent studies. Accumulating evidence points that circRNAs play an important role in the cellular processes, inflammatory expression, and immune responses through sponging miRNA, binding, or translating in proteins. Studies have found that circRNAs are involved in the physiologic and pathologic processes of diabetes. There has been an increased focus on the relevance of between abnormal circRNA expression and the development and progression of various types of diabetes and diabetes-related diseases. These circRNAs not only serve as promising diagnostic and prognostic molecular biomarkers, but also have important biological roles in islet cells, diabetes, and its complications. In addition, many circRNA signaling pathways have been found to regulate the occurrence and development of diabetes. Here we comprehensively review and discuss recent advances in our understanding of the physiologic function and regulatory mechanisms of circRNAs on pancreatic islet cells, different subtypes in diabetes, and diabetic complications.